The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Justin P. Kline and Thomas F. Gajewski.
Connection Strength

2.583
  1. Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol. 2012 Mar 15; 188(6):2630-42.
    View in: PubMed
    Score: 0.463
  2. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011 Apr; 23(2):286-92.
    View in: PubMed
    Score: 0.428
  3. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9.
    View in: PubMed
    Score: 0.426
  4. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res. 2008 May 15; 14(10):3156-67.
    View in: PubMed
    Score: 0.357
  5. MYC - a thorn in the side of cancer immunity. Cell Res. 2016 06; 26(6):639-40.
    View in: PubMed
    Score: 0.155
  6. Therapeutic activity of high-dose intratumoral IFN-? requires direct effect on the tumor vasculature. J Immunol. 2014 Oct 15; 193(8):4254-60.
    View in: PubMed
    Score: 0.139
  7. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest. 2013 May; 123(5):1999-2010.
    View in: PubMed
    Score: 0.126
  8. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011 Sep 26; 208(10):2005-16.
    View in: PubMed
    Score: 0.113
  9. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009 Aug 20; 114(8):1545-52.
    View in: PubMed
    Score: 0.096
  10. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009 May; 229(1):126-44.
    View in: PubMed
    Score: 0.095
  11. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006 Oct; 213:131-45.
    View in: PubMed
    Score: 0.080
  12. Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol. 2006 Oct 01; 177(7):4521-9.
    View in: PubMed
    Score: 0.080
  13. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.